MDxHealth (NASDAQ:MDXH - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data after the market closes on Wednesday, May 14th. Analysts expect MDxHealth to post earnings of ($0.13) per share and revenue of $22.62 million for the quarter.
MDxHealth (NASDAQ:MDXH - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.07. The firm had revenue of $24.74 million during the quarter, compared to analysts' expectations of $22.67 million. MDxHealth had a negative net margin of 49.52% and a negative return on equity of 1,077.84%. On average, analysts expect MDxHealth to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
MDxHealth Price Performance
NASDAQ MDXH remained flat at $1.72 during midday trading on Monday. 9,480 shares of the company's stock traded hands, compared to its average volume of 86,573. The stock has a fifty day moving average of $1.58 and a two-hundred day moving average of $1.86. MDxHealth has a 52 week low of $1.35 and a 52 week high of $3.50. The company has a debt-to-equity ratio of 3.14, a quick ratio of 1.45 and a current ratio of 1.54. The firm has a market cap of $81.34 million, a PE ratio of -1.13 and a beta of 1.29.
About MDxHealth
(
Get Free Report)
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.
See Also

Before you consider MDxHealth, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MDxHealth wasn't on the list.
While MDxHealth currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.